| Leistung |
Fallzahl |
OPS-Schlüssel |
Info |
|
407
|
9-693.11 |
|
|
261
|
9-696.52 |
|
| Regelbehandlung bei psychischen und psychosomatischen Störungen und Verhaltensstörungen bei Kindern und Jugendlichen |
216
|
9-656 |
|
|
211
|
9-693.10 |
|
|
205
|
9-693.12 |
|
|
182
|
9-696.55 |
|
|
93
|
9-696.58 |
|
|
86
|
9-696.32 |
|
|
76
|
9-696.13 |
|
|
67
|
9-696.31 |
|
|
67
|
9-696.33 |
|
|
66
|
9-696.11 |
|
|
65
|
9-696.12 |
|
|
61
|
9-696.35 |
|
|
59
|
9-696.14 |
|
|
57
|
9-696.0 |
|
|
57
|
9-696.10 |
|
|
57
|
9-696.15 |
|
|
56
|
9-696.30 |
|
|
55
|
9-696.37 |
|
|
53
|
9-696.17 |
|
|
52
|
9-696.36 |
|
| Elektroenzephalographie [EEG]: Routine-EEG (10/20 Elektroden) |
51
|
1-207.0 |
|
|
49
|
9-696.16 |
|
|
44
|
9-696.5b |
|
|
42
|
9-696.18 |
|
|
39
|
9-696.34 |
|
|
35
|
9-696.1g |
|
|
30
|
9-696.19 |
|
|
30
|
9-696.5e |
|
|
26
|
9-696.1b |
|
|
26
|
9-696.38 |
|
|
23
|
9-696.1e |
|
|
22
|
9-696.1a |
|
|
22
|
9-696.39 |
|
|
21
|
9-696.1d |
|
|
20
|
9-696.51 |
|
|
20
|
9-696.57 |
|
|
19
|
9-696.1c |
|
|
19
|
9-696.3b |
|
|
19
|
9-696.54 |
|
|
18
|
9-696.3a |
|
|
18
|
9-696.53 |
|
|
17
|
9-696.56 |
|
|
15
|
9-696.59 |
|
|
15
|
9-696.5m |
|
|
14
|
9-693.00 |
|
|
14
|
9-696.5d |
|
|
13
|
9-696.5h |
|
|
12
|
9-696.5c |
|
|
11
|
9-696.3g |
|
|
11
|
9-696.41 |
|
|
11
|
9-696.5a |
|
| Elektroenzephalographie [EEG]: Schlaf-EEG (10/20 Elektroden) |
10
|
1-207.1 |
|
|
10
|
9-696.5w |
|
|
9
|
9-649.0 |
|
|
9
|
9-696.5f |
|
|
9
|
9-984.7 |
|
|
8
|
9-696.1f |
|
|
8
|
9-696.3f |
|
|
7
|
9-696.21 |
|
|
7
|
9-696.3d |
|
|
7
|
9-696.40 |
|
|
7
|
9-696.5j |
|
|
7
|
9-696.5q |
|
|
7
|
9-984.b |
|
|
6
|
9-696.3c |
|
|
6
|
9-696.5g |
|
|
6
|
9-696.5n |
|
|
6
|
9-984.8 |
|
|
5
|
9-696.3e |
|
|
5
|
9-696.50 |
|
|
4
|
9-693.13 |
|
|
4
|
9-693.14 |
|
|
4
|
9-693.15 |
|
|
4
|
9-696.23 |
|
|
4
|
9-696.42 |
|
|
4
|
9-696.5k |
|
|
4
|
9-696.5t |
|
|
4
|
9-696.5u |
|
|
4
|
9-696.5v |
|
| Native Magnetresonanztomographie des Schädels |
k.A.
|
3-800 |
|
| Applikation von Medikamenten, Liste 1: Rituximab, intravenös: 1.050 mg bis unter 1.250 mg 1.050 mg bis unter 1.250 mg |
k.A.
|
6-001.h9 |
|
| Monitoring von Atmung, Herz und Kreislauf ohne Messung des Pulmonalarteriendruckes und des zentralen Venendruckes |
k.A.
|
8-930 |
|
| Regelbehandlung bei psychischen und psychosomatischen Störungen und Verhaltensstörungen bei Erwachsenen |
k.A.
|
9-607 |
|
| Psychiatrisch-psychosomatische Intensivbehandlung bei psychischen und psychosomatischen Störungen und Verhaltensstörungen bei Kindern und Jugendlichen |
k.A.
|
9-672 |
|
|
k.A.
|
9-696.22 |
|
|
k.A.
|
9-696.27 |
|
|
k.A.
|
9-696.44 |
|
|
k.A.
|
9-696.5p |
|
|
k.A.
|
9-696.5r |
|
|
k.A.
|
9-696.5s |
|
|
k.A.
|
9-984.6 |
|
